Please Wait
Applying Filters...
Menu
$ API Ref.Price (USD/KG) : 383,357Xls
Filters Filter
Cross PopUp
FILTER :

filter clear-filterReset all filters

01 1Nebulized Tyvaso

02 5Remodulin

03 4Tyvaso

04 1Tyvaso DPI

PharmaCompass

01

Brand Name : Remodulin

Treprostinil Sodium

arrow
2024 ACI Convention
Not Confirmed

02

Brand Name : Tyvaso

Treprostinil

arrow
2024 ACI Convention
Not Confirmed

03

Brand Name : Remodulin

Treprostinil Sodium

arrow
2024 ACI Convention
Not Confirmed

04

Brand Name : Tyvaso

Treprostinil

arrow
2024 ACI Convention
Not Confirmed

05

Brand Name : Tyvaso

Treprostinil

arrow
2024 ACI Convention
Not Confirmed

06

Brand Name : Remodulin

Treprostinil Sodium

arrow
2024 ACI Convention
Not Confirmed

07

Brand Name : Remodulin

Treprostinil Sodium

arrow
2024 ACI Convention
Not Confirmed

08

Brand Name : Tyvaso

Treprostinil

arrow
2024 ACI Convention
Not Confirmed

Brand Name : Tyvaso

arrow
2024 ACI Convention
Not Confirmed

Treprostinil

Main Therapeutic Indication : Cardiology/Vascular Diseases

Currency : USD

2022 Revenue in Millions : 873

2021 Revenue in Millions : 608

Growth (%) : 44

blank

09

Brand Name : Remodulin

Treprostinil Sodium

arrow
2024 ACI Convention
Not Confirmed

10

Brand Name : Tyvaso DPI

Treprostinil

arrow
2024 ACI Convention
Not Confirmed

Brand Name : Tyvaso DPI

arrow
2024 ACI Convention
Not Confirmed

Treprostinil

Main Therapeutic Indication : Cardiology/Vascular Diseases

Currency : USD

2023 Revenue in Millions : 731

2022 Revenue in Millions : 158

Growth (%) : 362

blank